Table 1.

Characteristics of patients entered on RTOG 9704 with GSK3β expression (n = 163)

≤Q3 (n = 123)>Q3 (n = 40)Pa
Age, y
 Median60630.21b
 Min–max35–8042–80
Gender0.76
 Male71 (57.7%)22 (55.0%)
 Female52 (42.3%)18 (45.0%)
Race0.75
 White113 (91.9%)36 (90.0%)
 African-American/Other10 (8.1%)4 (10.0%)
Primary tumor location0.25
 Head105 (85.4%)31 (77.5%)
 Neck/body/tail18 (14.6%)9 (22.5%)
KPS0.30
 60,70,8048 (39.0%)12 (30.0%)
 90,10075 (61.0%)28 (70.0%)
T stage0.44
 T1,T232 (26.0%)8 (20.0%)
 T3,T491 (74.0%)32 (80.0%)
N stage0.85
 N041 (33.3%)14 (35.0%)
 N182 (66.7%)26 (65.0%)
AJCC stage0.93
 I and II39 (31.7%)13 (32.5%)
 III and IV84 (68.3%)27 (67.5%)
Largest dimension of primary0.39
 <3 cm43 (35.0%)17 (42.5%)
 ≥3 cm80 (65.0%)23 (57.5%)
Primary tumor status0.93
 Complete resection/negative margins47 (38.2%)16 (40.0%)
 Complete resection/positive margins44 (35.8%)13 (32.5%)
 Complete resection/unknown margins32 (26.0%)11 (27.5%)
RX0.49
 RT + 5-FU60 (48.8%)22 (55.0%)
 RT + Gemcitabine63 (51.2%)18 (45.0%)
  • aP value from the χ2/Fisher exact test.

  • bKruskal–Wallis test.